Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 1998

View Archived Issues

Trimeris reports anti-HIV drug with a novel mechanism of action

Company Profile: Ventana Genetics

OCT: suppression of PTH secretion in mouse model of severe parathyroid hyperplasia

Neuroprotective effects demonstrated for novel sigma1-receptor agonist

Cyclic amines active against H. pylori in development at Takeda

Phosphodiesterase inhibitors with antiasthmatic efficacy

AIDS patients not taking their medications, new study shows

Anticancer activity of mEGP has been reported

Favorable results obtained in SomatoKine burn study

Nexell initiates phase I/II clinical trial of genetically corrected CD34 cells

PDE IV inhibitors focus of attention at recent respiratory care congress

Ribozyme's anticancer drug Angiozyme shows promise in preclinical trials

Genset announces discovery of novel prostate cancer-related gene

ArQule and Beth Israel enter collaboration for osteopenic disease drug discovery

Agouron's MMP inhibitor AG-3340 enters phase II/III trials

YF-476, a potent gastrin/CCK-B antagonist with gastric antisecretory activity

Wyeth-Ayerst has option to license Teikoku Hormone's antiandrogen

Spotlight on NK antagonists for asthma

Epix Medical: Q1 1998 highlights

Antiallergic/antiinflammatory effects of heparin and heparin fractions under evaluation

ImmunoGen: Q3 1998 and nine-month highlights

Oxigene: Q1 1998 highlights

Nikken initiates development of new anticancer agent

New direction taken in Toray's analgesic drugs program

BioChem Pharma initiates clinical testing of another AIDS drug

Bayer fluoroquinoline is effective against murine tuberculosis

FDA advisory committee requests additional information on Cryptaz

NCX-4016: a nitroderivative of aspirin with increased antiplatelet activity

FDA approves improved oral contraceptive agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...